Results 71 to 80 of about 23,951 (282)

Assessing blood donation applicant characteristics to optimize the promotion of apheresis

open access: yes, 2020
For effectively using blood products from a limited donor population, the promotion of apheresis donation should be emphasized more often. This study assessed the demographic data of apheresis applicants using blood donor data from the Japanese Red Cross
KAWAHARA, Kazuo   +2 more
core   +1 more source

Acute effects of low density lipoprotein apheresis on metabolic parameters of apolipoprotein B

open access: yesJournal of Lipid Research, 2000
Apheresis is a treatment option for patients with severe hypercholesterolemia and coronary artery disease. It is unknown whether such therapy changes kinetic parameters of lipoprotein metabolism, such as apolipoprotein B (apoB) secretion rates ...
Klaus G. Parhofer   +3 more
doaj   +1 more source

FAIRly deferred: Low impact of the individualised risk assessment policy on blood donor deferrals in England

open access: yesTransfusion Medicine, EarlyView.
Abstract Objectives To assess the impact of the individualised risk‐based donor selection guidelines on deferral of blood donors at donation sessions in England. Background From June 2021, the 3‐month deferral for sex between men was replaced by an individualised risk assessment known as FAIR (For the Assessment of Individualised Risk).
Katherine Daly   +3 more
wiley   +1 more source

Lipoprotein turnover and possible remnant accumulation in preeclampsia: insights from the Freiburg Preeclampsia H.E.L.P.-apheresis study

open access: yesLipids in Health and Disease, 2018
Background Preeclampsia is a life-threatening disease in pregnancy, and its complex pathomechanisms are poorly understood. In preeclampsia, lipid metabolism is substantially altered.
Christine Contini   +11 more
doaj   +1 more source

Functional validation of a modified platelet desialylation test for immune and hereditary thrombocytopenias

open access: yesTransfusion Medicine, EarlyView.
Abstract Background Thrombocytopenia arises from heterogeneous inherited and acquired disorders, and identifying the underlying platelet clearance mechanisms remains challenging. Platelet desialylation, characterised by loss of sialic acid and consequent exposure of terminal β‐galactose residues recognised by the Ashwell–Morell receptor, represents an ...
Karen Nogueira Chinoca Ziza   +14 more
wiley   +1 more source

Apheresis in Neurological Disorders [PDF]

open access: yesJournal of Clinical Medicine, 2020
Plasma exchange (PE) and immunoadsorption (IA) constitute important options in the treatment of various autoimmune disorders across different medical disciplines [...]
openaire   +3 more sources

Influence of LDL apheresis on LDL subtypes in patients with coronary heart disease and severe hyperlipoproteinemia

open access: yesJournal of Lipid Research, 2000
Epidemiologic studies and in vitro experiments indicate that low density lipoprotein (LDL) subtypes differ concerning their atherogenic potential. Small, dense LDL are more atherogenic than large, buoyant LDL.
B.M. Schamberger   +4 more
doaj   +1 more source

Anaphylactic transfusion reaction to group B platelets related to alpha‐gal syndrome: A case report

open access: yesTransfusion, EarlyView.
Abstract Background Alpha‐gal syndrome (AGS), a distinct form of IgE‐mediated hypersensitivity to the carbohydrate galactose‐α‐1,3‐galactose (α‐Gal), typically occurs after repeated tick bites and leads to allergic reactions after ingestion of mammalian meat.
Oscar Andre Hinojosa   +2 more
wiley   +1 more source

Glycemic control and blood product quality of Canadian blood donors with diabetes

open access: yesTransfusion, EarlyView.
Abstract Background Many blood centers now accept donors with diabetes, provided their condition is “well‐controlled”. However, glycemic control is not routinely assessed at donation, and the impact of donor diabetes on blood product quality remains unclear.
Elyn M. Rowe   +7 more
wiley   +1 more source

Impaired hematopoiesis affects apheresis and CAR T‐cell product composition and treatment response

open access: yesTransfusion, EarlyView.
Abstract Background Chimeric antigen receptor (CAR) T‐cell therapy has transformed the treatment of hematologic malignancies, but its success depends on obtaining sufficient CD3+ T‐cell yields during leukapheresis. This can be difficult in heavily pretreated patients, who often show leukopenia and reduced T‐cell fitness.
Hanna Kuhn   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy